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ABSTRACT 2 
Using in vivo 1H NMR spectroscopy in a mouse model of Parkinson's disease, we previously 3 
showed, that glutamate concentrations in the dorsal striatum were highest after dopamine denervation 4 
associated with an increase in GABA and glutamine levels. The aim of this study was to determine 5 
whether the changes previously observed in the motor part of the striatum were reproduced in a ventral 6 
part of the striatum, the nucleus accumbens (NAc). This study was carried out on controls and MPTP-7 
intoxicated mice.  In vivo spectra were acquired for a voxel (8 µl) in the dorsal striatum, and in the 8 
NAc (1.56 µl). NMR acquisitions were first performed 10 days after the last MPTP injection in basal 9 
condition (after saline i.p. injection) and then in the same animal the week after basal NMR 10 
acquisitions, after acute levodopa administration (200mg.kg-1, i.p.). Immunohistochemistry was used 11 
to determine the levels of glutamate, glutamine synthetase (GS) and GAD67 in these two structures. 12 
The glutamate, glutamine and GABA concentrations obtained in the basal state were higher in the 13 
NAc of MPTP-intoxicated mice which have the higher dopamine denervation in the ventral tegmental 14 
area (VTA) and in the dorsal striatum. Levodopa decreased the levels of these metabolites in MPTP-15 
intoxicated mice to levels similar to those in controls. In parallel immunohistochemical staining 16 
showed that glutamate, GS and GAD67–immunoreactivity increased in the dorsal striatum of MPTP-17 
intoxicated mice and in NAc for animals with a severe dopamine denervation in VTA.  18 
These findings strongly supported a hyperactivity of the glutamatergic cortico-striatal pathway and 19 
changes in glial activity when the dopaminergic denervation in the VTA and SNc was severe. 20 
Keywords: MPTP-intoxicated mice, 1H NMR spectroscopy, Glu, Gln, GABA, dorsal striatum, NAc 21 
22 
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INTRODUCTION  23 
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by a severe 24 
loss of dopaminergic neurons (DA neurons) close to 80% in the ventral part of the midbrain 25 
corresponding principally to the substantia nigra pars compacta (SNc) (1,2). Dopamine denervation is 26 
less severe (40 %), in the dorsal SNc and the contiguous ventral tegmental area (VTA) which belongs 27 
to the dorsal part of the midbrain (3-5). These nuclei  project to the ventral striatum, which includes 28 
the nucleus accumbens (NAc) and the broad continuum between the caudate nucleus and the putamen 29 
ventral to the rostral internal capsule, the limbic cortex (medial prefrontal, cingulate and entorhinal 30 
areas) and other limbic structures (septum, olfactory tubercle, amygdalus, hippocampus, pyriform 31 
cortex) (6). Degeneration of the DA neurons in the SNc causes a large concomitant decrease in 32 
dopamine levels within the dorsolateral striatum (2). This part of the striatum is connected to the 33 
premotor and motor cortices areas (7,8). Using 1H NMR spectroscopy to measured the levels of 34 
GABA and glutamate (Glu) in the dorsal striatum, we previously demonstrated significant increased 35 
Glu and GABA concentrations in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-intoxicated 36 
C57Bl/6J mice (9,10). MPTP is a known neurotoxin which affects primarily (though not exclusively) 37 
the dopamine-containing neurons of the SNc. It has subsequently been used to establish a mice model 38 
of PD (11). Thus, our studies strongly suggest that the motor glutamatergic cortico-striatal pathway 39 
displays hyperactivity after MPTP intoxication accompanied by an increase in striatal GABA levels. 40 
DA denervation of the VTA induces a decrease in dopamine levels within the NAc depending on the 41 
size of the VTA lesion (12-14). Damage to the mesocorticolimbic DA pathway may contribute to the 42 
non- motor symptoms described during the progression of PD, such as apathy (15) and depression (16-43 
18). However, the consequences of DA denervation in the VTA for Glu and GABA levels in the NAc 44 
remain unclear. Only one study has shown an increase in levels of the mRNA for isoform 67 of 45 
glutamic acid decarboxylase (GAD67), an enzyme involved in GABA-synthesis, in the anterior part 46 
and core of the NAc after DA denervation (19). These results suggest that dopamine exerts a tonic 47 
inhibitory control over GAD67 mRNA synthesis in the NAc, in normal conditions. 48 
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The objective of this study was to assess the consequences of DA denervation of the VTA and the SNc 49 
after MPTP intoxication in mice for the glutamatergic and GABAergic activities in the two target 50 
structures, the NAc and the dorsal striatum. In vivo 1H NMR spectroscopy was used to determine the 51 
levels of Glu, GABA and Gln in the NAc and the dorsal striatum of the MPTP-intoxicated mouse 52 
model of PD before and after DA replacement (intraperitoneal i.p. injection of the precursor of the 53 
dopamine, the levodopa). The concentrations obtained in the NAc were compared with the 54 
concentrations of Glu, GABA and Gln found in the dorsal striatum. We have chosen MRS due to its 55 
ability to make repeated direct non-invasive measurements of brain metabolites in vivo. Measurement 56 
of these metabolites concentrations using 1H MRS is one way to assess Glu and GABA 57 
neurotransmitters release and glial-neuronal interactions (20,21). We also used immunohistochemistry 58 
to determine the levels in the dorsal striatum and the NAc t of Glu, glutamine synthetase (GS), an 59 
ubiquitous enzyme present in the astroglial cytoplasm and involved in the conversion of Glu to Gln 60 
(22), and GAD67. 61 
 62 
EXPERIMENTAL PROCEDURES 63 
Animals - All experiments were performed according to procedures conforming to European 64 
legislative, administrative and statutory regulations governing the protection of animals used for 65 
experimentation or other scientific purposes (86/609/EEC). The study design was approved by the 66 
Regional Experimental Care and Use Committee (Auvergne CREEA). The permit number for this 67 
study was CE 8-06.  68 
We used male C57Bl/6J (Charles River, L’Arbresle, France) mice aged seven weeks and weighing 19 69 
to 20g at the start of experiment. They were housed at 20-22°C under a 12-hour light/12-hour dark 70 
cycle.  71 
Four control mice were used for specific localization of the NAc, with the aim of positioning the voxel 72 
of interest (VOI) precisely on MR images for NMR spectroscopy acquisitions. These mice were 73 
anesthetized and fitted with a cannula (outer diameter=0.23mm and length=4.5mm) implanted 74 
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unilaterally at the stereotaxic coordinates of the NAc, defined as in the Paxinos and Franklin (23) 75 
mouse brain atlas (coordinates with respect to bregma: A: +1.5 mm, L=0.9 mm, V=-4.0 mm). One 76 
week after surgery, MR images were acquired to visualize the trace left by the cannulae, to define 77 
anatomical landmarks and thus to localize the NAc precisely, to ensure the reproducible positioning of 78 
the VOI in the NAc.  79 
Forty mice received i.p. injections, once daily, at 2.00 pm, for five days, of saline (0.1 ml) (20 saline-80 
treated mice, controls) or an equivalent volume of 25 mg.kg-1 1-methyl-4-phenyl-1,2,3,6-81 
tetrahydropyridine (MPTP; Sigma-Aldrich, St Louis, MO, USA) in saline (20 MPTP-intoxicated 82 
mice), as previously described (9,24). From them, twenty mice (10 controls and 10 MPTP-intoxicated 83 
mice) were assessed by behavioral tests and the other twenty mice were used for 1H NMR 84 
spectroscopy and immunohistochemistry analysis. 85 
Behavior - All behavior tests were carried out between 8.00 am and 1.00 pm, for both groups 86 
of animals. The rotarod (25,26) and pole tests (26,27) were started the morning before the first saline 87 
or MPTP injection (d-5) and were performed three days (d3) and ten days (d10) after the last injection 88 
(fig 1). On d10, animals were tested 60 minutes after the i.p. administration of saline (0.2 ml) and the 89 
following day (d11), 60 minutes after levodopa/benserazide i.p. administration at the dose that we 90 
previously used: 200 mg.kg-1/75 mg.kg-1 in 0.2 ml saline (10).  91 
Rotarod test - The animals were positioned on the rotarod (TSE systems GmbH, Bad Homburg, 92 
Germany). The rotarod was programmed to rotate such that its speed increased linearly from 4 to 40 93 
rpm in 300 seconds. An automatic sensor was used to determine the point at which the animals fell off 94 
the rod and to calculate the total time, in seconds, spent on the rod. On the days of testing, mice were 95 
trained to stay on the rod during three 60 s sessions, separated by intervals of 10 minutes. The rod did 96 
not turn at all during the first training session, and it turned at a fixed of 4 rpm in the two next. The test 97 
phase started 30 minutes later and consisted of four successive trials separated by 15-minute inter-trial 98 
intervals. The mean total time spent on the rod in the four trials was determined and is given together 99 
with the standard deviation (SD) for each group. 100 
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Pole test - The pole test involved the use of a 50 cm high wooden pole, 0.5 cm in diameter, wrapped in 101 
gauze to prevent slipping and positioned with the base in the home cage (26,27). An eraser was glued 102 
on top of the pole to help position the animals on the pole. The time at which the animal turned nose 103 
down (Tturn in s) and the total time required to climb down the pole (locomotion activity time, TLA in s) 104 
were measured, with a maximum value of 120 s. If the mouse failed to turn nose down and instead 105 
dropped from the pole, TLA was taken as 120 s (the default value), because this was assumed to 106 
indicate the maximal severity. During testing sessions at d-5, d3 and d10, each animal underwent three 107 
successive trials, with a five-minute interval between trials. The data presented are the scores obtained 108 
during the third trial and are expressed as the mean ± SD for each group of animals. 109 
In vivo 1H NMR spectroscopy - In vivo NMR spectra were acquired at 9.4 T, on a Bruker 110 
Avance DRX 400 micro-imaging system with a wide-bore vertical magnet and an actively shielded 111 
gradient coil (Bruker, Ettlingen, Germany). The animals were assessed between 10 and 17 days after 112 
the last MPTP or saline injection (fig 1: d10 to d17) and NMR spectra were acquired after saline 113 
administration (0.2 ml; i.p.). To assess the impact of levodopa administration on the metabolites 114 
amounts, one week later each animal was assessed again (fig 1: d17 to d24) after levodopa/benserazide 115 
administration (i.p.; 200 mg.kg-1/75 mg.kg-1 in 0.2 ml saline). The animals were anesthetized by 116 
spontaneous inhalation, through a mask, of 1-2.4 % isoflurane and air (300 ml.min-1). They were 117 
carefully secured in a Bruker MicroMouse 2.5 animal handling system with their heads positioned in 118 
the center of a 20 mm diameter birdcage radiofrequency coil for excitation and signal reception. The 119 
air temperature surrounding the mouse chamber was maintained at 39°C by the circulation of warm 120 
air, under the control of a heat sensor. The mice breathed freely during the NMR acquisition and the 121 
concentration of anesthetic was adjusted to maintain respiratory rate close to 80 bpm. 122 
The positions of the VOIs were determined on T2-weighted images (a single-shot multi echo -RARE 123 
sequence- echo time 36 ms, recycling time 4.5 s, 19 slices 0.8 mm thick) in accordance with data from 124 
the Paxinos and Franklin atlas (23). The dorsal striatum VOI was 8 µl (2×2×2 mm) in size. The 125 
position of the NAc VOI was determined from anatomical landmarks defined by viewing the trace left 126 
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by the cannula on the magnetic resonance images in relation with the mouse brain atlas. The 127 
anatomical landmarks were the end of the lateral ventricle and the anterior part of the anterior 128 
commissure. The NAc VOI was 1.56 µl (1.16×1.16×1.16 mm) in size. NMR spectra were obtained for 129 
both structures, for each animal. All first- and second-order shim terms were manually adjusted for the 130 
VOIs. Generally, a half-height linewidth of the water signal of 12 Hz was achieved in the dorsal 131 
striatum. The linewidth of the water signal was around 15 Hz in the NAc voxel. A point-resolved 132 
spectroscopy sequence (PRESS) was used for located signal acquisition (TE = 8.8 ms; TR = 4000 ms; 133 
spectral width = 5000 Hz). The water signal from the VOIs was suppressed by variable-power RF 134 
pulses with optimized relaxation delays (VAPOR) (28). Each spectrum acquired for the dorsal 135 
striatum corresponded to a mean of 512 scans whereas each spectrum acquired for the NAc 136 
corresponded to a mean of 1024 scans. A spectrum was acquired in the same conditions without 137 
VAPOR water suppression for the absolute quantification of metabolites. For brain 1H NMR 138 
spectroscopy, resonances of low-molecular weight metabolites, such as lactate (Lac), N-acetyl 139 
aspartate (NAA), total creatine (creatine and phosphocreatine; tCr), total choline 140 
(glycerophosphocholine and choline; tCho), glutamate + glutamine (Glx) and myo-inositol (Myo-Ins) 141 
overlapped with those of macromolecules (proteins and lipids). To minimize the contribution of 142 
macromolecules to the absolute quantification of the metabolites, we acquired a macromolecules 143 
spectrum applying the metabolite-nulling technique (29,30). A PRESS sequence was used with an 144 
extra inversion pulse. Before this study, the inversion time recovery (TI) was adjusted to nullify the 145 
metabolite signal in the dorsal striatum and NAc of four mice. A TI of 923 ms was defined. 146 
To correct the metabolite concentration, the T1 and T2 relaxation times of water and NAA, tCr, tCho, 147 
Glx, Tau and Myo-Ins were calculated from spectra acquired in the two voxels, as previously 148 
published (9,10). Each spectrum corresponded to a mean of 4 or 128 scans for water and metabolites 149 
T1 and T2 determinations, respectively. Signals were acquired with an echo time of 8.8 ms and five 150 
different recycling times (TR1-5 = 1000/2000/4000/8000/10000 ms) for longitudinal relaxation time 151 
(T1) measurements and with TR=4000 ms and 10 different echo times (TE1-10 = 152 
A severe DA denervation in VTA induces metabolite change in the NAc 
 
8 
 
8.8/20/30/40/60/80/100/130/180/250 ms) for transversal relaxation time (T2) measurements. The 153 
relaxation times (T1 and T2) measured were in accordance with those previously published (9). 154 
In vivo metabolite concentrations were determined from VOI spectra after subtraction of the 155 
macromolecules spectrum with jMRUI software. The quantification method used was the time-domain 156 
semi-parametric algorithm QUEST, based on signals for a basis set of simulated metabolites. This 157 
basis set of metabolites included the following nine molecules: tCr, tCho, GABA, Glu, Gln, Lac, Myo-158 
Ins, NAA and Tau. The intensity of the water signal obtained from non- suppressed water spectra was 159 
used as an internal reference. For this purpose, we determined the brain water content for four control 160 
mice and four MPTP-intoxicated mice. Animals were killed by decapitation and their brains were 161 
quickly removed and dried in a drying oven. The percentage water content was calculated from the 162 
difference in weight between the freshly removed whole brain and its residue after dehydration. The 163 
water content of controls mouse brain was 78.6% ± 2.4%, whereas that of MPTP-intoxicated mouse 164 
brain was 79.6% ± 1.8% (values similar to published data, 9,31,32). We assumed the visibility of the 165 
water signal to be 100% and used a water molarity of 55.5M. Corrections were performed to take 166 
account of the T2 and T1 effects of water and metabolites, as previously described (9,10). For each 167 
metabolite, we applied the T1 correction factor (1/1-exp
(-TR/T1)) with TR=4s and the T2 correction factor 168 
(1/exp(-TE/T2)) with TE=8.8 ms. 169 
The reliability of metabolite quantification was assessed from the average Cramer-Rao lower bounds 170 
(CRLB) calculated by jMRUI. CRLB are estimates of the % SD of the fit for each metabolite (33,34). 171 
Only results with a CRLB ≤ 30% were included in the analysis. In vivo results are expressed in mM, as 172 
means ± SD.  173 
Immunohistochemical labels- 174 
Tissue preparation - Following the acquisition of NMR spectra, five controls and five MPTP-175 
intoxicated mice chosen at random were killed 60 minutes after the i.p. injection of saline. Five 176 
controls and five MPTP-intoxicated mice, also chosen at random were killed 60 minutes after the i.p. 177 
injection of levodopa/benserazide (i.p.; 200 mg.kg-1/75 mg.kg-1 in 0.2 ml saline). These animals were 178 
A severe DA denervation in VTA induces metabolite change in the NAc 
 
9 
 
deeply anesthetized with sodium pentobarbital (180 mg.kg-1; i.p.) and then transcardially perfused with 179 
4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). Their brains were removed, post-fixed by 180 
incubation in the same buffer for 1 h at 4°C and included in paraffin. We prepared 7 µm coronal 181 
sections from the substantia nigra (SNc) and the ventral tegmental area (VTA) for tyrosine 182 
hydroxylase (TH) immunohistochemistry, to validate the DA loss after MPTP intoxication. We also 183 
prepared 7 µm coronal sections from the dorsal striatum and the NAc for glutamate (Glu), glutamate 184 
decarboxylase (GAD) isoform GAD67 and glutamine synthetase (GS) analyses. 185 
Immunohistochemical staining - Tissue sections were deparaffinized by incubation with xylene and 186 
were then rehydrated. Antigen retrieval was performed by bringing slides to the boil in 10 mM sodium 187 
citrate, pH 6.0, maintaining them just below boiling point for 20 minutes, and then cooling them at 188 
20°C for 20 minutes. The sections were then washed for five minutes in distilled water and 10 minutes 189 
in wash buffer [0.1% Tween 20, 50 mM NaF in 1X Tris-buffer saline (TBS)], then incubated for 10 190 
minutes in buffer containing 3% H2O2 (Peroxidase blocking solution DAKOCytomation, Carpinteria, 191 
CA, USA). They were then washed again in the wash buffer for 10 minutes. The SNc and VTA 192 
sections were incubated overnight at 4°C with a rabbit polyclonal anti-TH antibody (1:500; Chemicon 193 
International, Temecula, CA, USA). The dorsal striatum and NAc sections were incubated overnight 194 
at 4°C with a rabbit polyclonal anti-Glu antibody (1:5; Chemicon International), a mouse monoclonal 195 
anti-GAD67 antibody (1:500; Chemicon International), or a mouse monoclonal anti-GS antibody 196 
(1:300; Chemicon International). The slides were washed and treated with biotinylated secondary 197 
antibody (Kit LSAB + System-HRP, DAKOCytomation) for 30 minutes at 20°C. The slides were then 198 
washed in 0.1% Tween 20 in 1X TBS, incubated for 30 minutes at 20°C with streptavidine-HRP 199 
complex (DAKOCytomation) and washed again in 0.1% Tween 20 in 1X TBS. Diaminobenzidine 200 
substrate (DAKOCytomation) was added and the slices were incubated at 20°C. The reaction was 201 
stopped by immersing the slides in distilled water, and the slides were sealed for visualization by light 202 
microscopy. 203 
A severe DA denervation in VTA induces metabolite change in the NAc 
 
10 
 
Quantitative analysis of immunostained cells - The immunostained cells were counted automatically 204 
on recorded images, with IPS 32 software (SAMBA 2005, SAMBA Technologies, Meylan, France). 205 
For each group of animals, we show the total number of positive cells, expressed as mean ± SD. 206 
Statistical analysis - NMR data were compared by two-way analysis of variance (ANOVA) with 207 
repeated measures for one factor (treatment: saline and levodopa). A Dunnett post-hoc test was carried 208 
out if the ANOVA was significant. Behavioral data were compared by repeated measures ANOVA, 209 
followed by a Newman-Keuls post-hoc test if the ANOVA was significant. The numbers of 210 
immunostained cells in the four groups of mice were compared in a two-way ANOVA, which was 211 
followed by a Dunnett post-hoc test if the ANOVA was significant. Analyses were performed with 212 
SAS V.8.1 statistical software (Cary, NC, USA). The concentrations of GABA, Glu and Gln in the 213 
NAc, as determined by NMR spectroscopy, are expressed as a function of the number of TH-214 
immunoreactive cells in the VTA. Linearity was assessed by calculating the correlation coefficient r. 215 
 216 
RESULTS 217 
Number of dopaminergic neurons in the SNc and VTA - MPTP intoxication significantly 218 
decreased (by 85 %) the mean number of TH-immunoreactive neurons in the SNc, as shown by 219 
comparison with control values (fig 2; 66 ± 13 vs 428 ± 36 TH-immunoreactive positive cells, 220 
respectively; p < 0.001). Levodopa administration had no impact on the number of TH-221 
immunoreactive neurons in the SNc of controls (428 ± 36 vs. 417 ± 54) or of MPTP-intoxicated mice 222 
(66 ± 13 vs. 63 ± 17). The mean number of TH-immunoreactive neurons in the VTA decreased by 44 223 
% after MPTP intoxication (fig 2; 88 ± 13 TH-immunoreactive positive cells for controls vs 49 ± 10 224 
TH-immunoreactive positive cells for MPTP-intoxicated mice; p < 0.05). Levodopa administration 225 
also had no effect on the number of TH-immunoreactive neurons in the VTA of controls (88 ± 13 vs 226 
90 ± 8) or of MPTP-intoxicated mice (49 ± 10 vs 43 ± 12). DA denervation was homogeneous in the 227 
SNc, while there was a large interindividual variation of the lesion in the VTA (see below). 228 
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Behavior changes after MPTP intoxication - The performance of control and MPTP-229 
intoxicated animals in the rotarod test (fig 3) was assessed as the total time spent on the rod, expressed 230 
in seconds. The animals in the control group spent significantly more time on the rod in the third trial 231 
session (d10) than at d-5 and d0 (d10: 164 ± 9 s vs d-5: 103 ± 10 s and vs d3: 114 ± 10 s; **p<0.01). 232 
Significantly more time was spent on the rod on d10, than on the following day, after levodopa 233 
administration (200 mg.kg-1; i.p.) (d10: 164 ± 9 s vs d11: 127 ± 15 s; **p<0.01). Whereas controls 234 
performed significantly better in the third assessment than during the first two assessments, MPTP-235 
intoxicated mice spent similar amounts of time on the rod at d-5, d3 and d10. Levodopa administration 236 
significantly improved rotarod performance in MPTP-intoxicated mice (d11: 157 s ± 14 s vs d10: 116 237 
± 9 s; **p<0.01). Thus, controls spent more time on the rod than MPTP-intoxicated mice at d10 (164 s 238 
± 9 s vs 116 s ± 9 s; #p<0.05) but less time than MPTP-intoxicated mice on day 11, after levodopa 239 
administration (127 s ± 15 s vs 157 s ± 14 s; #p<0.05).  240 
In the pole test, MPTP-intoxicated mice needed significantly more time to turn completely than 241 
controls at d10 (fig 4A: MPTP-intoxicated mice: 7.1 ± 2.6 s vs controls: 2.2 ± 0.4 s; ##p<0.01). 242 
Furthermore MPTP-intoxicated mice required significantly longer to turn at d10 than before MPTP 243 
injection (d10: 7.1 ± 2.6 s vs d-5: 1.9 ± 0.2 s; **p<0.01). Levodopa administration (200 mg.kg-1; i.p.) 244 
at d11 tended to decrease the amount of time required for turning, but this difference was not 245 
significant (d10: 7.1 ± 2.6 s vs d11 (+Ldopa): 4.4 ± 1.1 s; p=0.13). The time required for the control 246 
mice to turn did not differ between the three testing sessions, but these mice tended to take longer to 247 
reach the floor after levodopa administration (200 mg.kg-1; i.p.). At d10, MPTP-intoxicated mice 248 
required significantly longer to reach the floor than control mice (fig 4B: MPTP-intoxicated mice: 249 
13.7 ± 2.9 s vs controls: 8.2 ± 0.9 s; #p<0.05). Furthermore, the time required for MPTP-intoxicated 250 
mice to reach the floor at d10 was significantly greater than that before MPTP injection (d10: 13.7 ± 251 
2.9 s vs d-5: 7.6 ± 0.7 s; **p<0.01). Levodopa administration at d11 significantly decreased this time 252 
(d10: 13.7 ± 2.9 s vs d11 (+Ldopa): 9.7 ± 1.5 s; *p<0.05).  253 
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Metabolite levels in the dorsal striatum and NAc, as assessed in vivo by 1H-NMR spectroscopy 254 
- In vivo 1H NMR spectra for the corresponding brain regions are shown in figure 5. The spectra 255 
shown in figure 5A were acquired from the dorsal striatum of a control mouse and a MPTP-256 
intoxicated mouse after saline injection and levodopa (200 mg.kg-1) administration. Those in figure 5B 257 
were from the NAc. The resulting high degree of spectral resolution permitted unequivocal signal 258 
assignment. In addition to the usual signals for NAA (2.008 ppm), tCr (3.022 ppm) and tCho (3.22 259 
ppm), the resonances of several brain metabolites Glu (2.34 ppm), Gln (2.42 ppm), GABA (2.28 ppm), 260 
Lac (1.33 ppm), Tau (3.24-3.42 ppm) and Myo-Ins (3.48-3.52 ppm) were clearly resolved. Thus, nine 261 
brain metabolites were reliably quantified. NAA, tCr, Tau and Glu were quantified in the two brain 262 
regions with Cramer-Rao lower bounds (CRLB, defined by the jMRUI software) ≤ 12% (data not 263 
shown). Gln, GABA, tCho, Myo-Ins and Lac were quantified with CRLB between 15 and 30%. 264 
For controls, the metabolites profile obtained for the NAc and dorsal striatum were similar in the basal 265 
state (fig 5).  266 
The Glu, Gln and GABA concentrations obtained in vivo in the basal state were significantly higher in 267 
the dorsal striatum of MPTP-intoxicated mice than in that of controls (fig 6A; Glu: 19.1 ± 1.5 vs. 10.6 268 
± 2.3 mM, ***p < 0.001; Gln: 5.9 ± 1.6 vs. 2.6 ± 1.1 mM, *p < 0.05; GABA: 3.9 ± 0.9 vs. 2.1 ± 0.5 269 
mM, *p < 0.05). Levodopa decreased metabolite levels in the dorsal striatum of MPTP-intoxicated 270 
mice (Glu: 19.1 ± 1.5 vs. 10.2 ± 3.4 mM, ###p < 0.001; Gln: 5.9 ± 1.6 vs. 2.5 ± 0.9 mM, #p < 0.05; 271 
GABA: 3.9 ± 0.9 vs. 2.0 ± 0.8 mM, #p < 0.05). Metabolite levels in the dorsal striatum of MPTP-272 
intoxicated mice treated with levodopa did not differ significantly from those in the dorsal striatum of 273 
controls. DA denervation in VTA and replacement with levodopa had no effect on the mean 274 
metabolite levels the NAc (fig 6B).   275 
While individual data for MPTP-intoxicated mice obtained in the striatum and the percentage of DA 276 
denervation of the SNc were homogeneous (fig 7A), those measured in the NAc showed that GABA, 277 
Glu and Gln levels were the higher for animals which had a severe DA denervation, which were 278 
decreased after levodopa administration (fig 7B). A DA denervation of 59% in the VTA (mean 279 
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denervation for the three animals which have the more severe DA denervation in the VTA) was 280 
necessary to induce changes in metabolites levels. Furthermore, the concentrations of GABA, Glu and 281 
Gln in the NAc were significantly and inversely correlated with the number of TH-immunoreactive 282 
neurons in the VTA (respectively r = -0.7834, p<0.05; r = -0.9896, p<0.01 and r = -0.8403, p<0.05).  283 
GAD67, Glu and GS labeling in the dorsal striatum and NAc - Immnuohistochemical labeling 284 
of GABAergic neurons with a monoclonal GAD67 antibody revealed a high density of intensely 285 
stained neurons throughout all parts of the dorsal striatum and the NAc (fig 8A). Labeling with the 286 
anti-Glu antibody revealed the presence of a high density of Glu-positive granules in the dorsal 287 
striatum and NAc, corresponding to the intra- and extracellular pool of Glu. GS immunoreactivity was 288 
demonstrated in the cytoplasm and processes of glial cells in the two areas of the brain studied.  289 
In the dorsal part of the striatum, MPTP intoxication increased the number GAD67-positive neurons to 290 
levels significantly higher than those for controls (fig 8B; 2883 ± 238 vs 1501 ± 64; p<0.001). The 291 
number of Glu-positive granules was also higher in the dorsal striatum of MPTP-intoxicated mice than 292 
controls (11455 ± 1560 vs 5399 ± 446; p<0.01). Furthermore, the number of GS-positive astrocytes 293 
was significantly higher in the dorsal striatum of MPTP-intoxicated mice than in that of controls (7283 294 
± 585 vs 3440 ± 454; p<0.01). Levodopa administration had no impact on the number of GAD-295 
immunoreactive neurons, Glu-positive granules and GS-positive astrocytes in the dorsal striatum of 296 
controls and MPTP-intoxicated mice. DA denervation or replacement with levodopa had no impact on 297 
the mean number of positive neurons, granules and astrocytes in the NAc (fig 8B). However, 298 
individual data showed that GAD67, Glu and GS positive cells assessed in the NAc were higher for 299 
animals which had a severe DA denervation in the VTA (fig 9B).  300 
 301 
DISCUSSION 302 
This work illustrated the possibility to follow in vivo, using short-echo PRESS NMR localized 303 
spectroscopy, the metabolites levels in a small volume (1.56 µl) encompassing the NAc. We first 304 
showed that the metabolic profile of this structure was identical to this obtained in the dorsal striatum. 305 
A severe DA denervation in VTA induces metabolite change in the NAc 
 
14 
 
Secondly, the MPTP intoxication of the mice increased GABA, Glu and Gln concentrations in the 306 
dorsal striatum and in the NAc showing that the DA denervation was sufficient in the VTA (>59%). 307 
Thirdly, levodopa decreased metabolite levels in the dorsal striatum of MPTP-intoxicated mice and in 308 
the NAc for MPTP-intoxicated animals which showed the highest levels of GABA, Glu and Gln. 309 
Finally, changes in metabolites concentrations in the dorsal striatum and in the NAc were associated 310 
with changes in Glu metabolism, as shown by immunohistochemistry and characterized by an increase 311 
in the number of GAD67-reactive-neurons, Glu-positive granules and GS-positive astrocytes. 312 
 313 
 In this study, jMRUI fitting to the spectra acquired for the NAc yielded the same 314 
neurochemical profile as obtained for the dorsal striatum. Anatomically, the NAc is a major part of the 315 
ventral striatum and the cell types present are similar to those in the dorsal striatum. Indeed, 90% of 316 
the neurons in the NAc are GABAergic medium spiny neurons and the axon terminals in the NAc are 317 
mainly DA terminals from the VTA and glutamatergic neurons from the prefrontal cortex (35). It is 318 
therefore not particularly surprising that the metabolic profiles of these two structures are similar.   319 
Glu and GABA levels in the dorsal striatum, as assessed by 1H NMR spectroscopy were 320 
dramatically increased after MPTP intoxication. Changes were also observed in the NAc for animals 321 
which had the most severe VTA denervation (>59%).  In fact, change in metabolites levels in the 322 
striatum depends on the severity of the dopaminergic lesion of the SNc and the VTA, which induces in 323 
turn a dramatic decrease of dopamine level in the dorsal and ventral striatum. Indeed, all studies which 324 
reported changes in glutamatergic cortico-striatal and GABAergic activity in the dorsal striatum have 325 
been shown in animal models to display a decrease of more than 60% in the number of DA neurons in 326 
SNc (9,10,36). Furthermore, Retaux et al. (19), showed that a bilateral total electrolytic lesion of the 327 
VTA in the rat induced an increase in GAD67 mRNA levels in the anterior and core part of the NAc. 328 
In our study, MPTP intoxication decreased the number of DA neurons by a mean of 85% in the SNc, 329 
and 44% in the VTA which may explain why no significant change of mean metabolites levels was 330 
observed in the NAc. The different profile of dopaminergic denervation in the SNc and the VTA could 331 
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be due to a specific sensivity of dopaminergic neurons to MPTP. A more severe dopaminergic 332 
denervation in the SNc than in the VTA is commonly observed in other studies using MPTP (37-39). 333 
Furthermore, in PD, highly vulnerable DA subpopulations within the SNc and their axonal projections 334 
to dorsal parts of the striatum are almost completely lost, whereas neighboring DA subpopulations 335 
within the VTA and their projections to the NAc have much higher survival rates (1,40). The 336 
dopamine deficiency is thus much greater in the dorsal striatal than in the NAc (12). 337 
Taken together, these results suggest that changes in metabolites levels in the NAc and the dorsal 338 
striatum may be linked to the severity of DA denervation in the VTA and the SNc and could be used 339 
as marker of the severity of the disease. Other studies assessing the relationship between the severity 340 
of the dopaminergic lesion in SNc and VTA and the change in striatal metabolite levels are mandatory 341 
to confirm this hypothesis. 342 
 The increase in Glu levels observed after MPTP intoxication was consistent with the increase 343 
in the number of Glu-positive granules observed on immunohistolabeling. It confirmed our previous 344 
results (9,10) and it was in accordance with several other studies showing long-term changes in 345 
excitatory striatal inputs after dopamine depletion, such as an increase in striatal Glu release, in mean 346 
percentage of asymmetrical synapses and phosphorylation, and in the abundance of Glu receptor 347 
subunits (36,41-44). The high levels of GABA after MPTP intoxication were consistent with the 348 
increase in the number of GAD67-immunoreactive neurons in the dorsal striatum and the NAc of 349 
dopamine-depleted mice. These changes were due to an increase in the basal activity of striatal 350 
neurons following DA denervation, because GAD67 expression is considered to be an index of 351 
GABAergic striatal efferent neuron activity (45,46). And several other studies showed an increased in 352 
the electrical activity of GABAergic neurons (47), the enhanced release of GABA (48) and an increase 353 
in GAD67 mRNA levels (49).  354 
Finally, the increase in Gln levels after MPTP intoxication was associated with higher GS 355 
immunolabeling in the dorsal striatum and in the NAc of MPTP-intoxicated mice. These results 356 
suggested that DA denervation modifies glial activity. Similarly, a recent study clearly demonstrated a 357 
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relationship between GLT-1, a glial high-affinity Na+/K+-dependent Glu transporter, and changes in 358 
extracellular Glu levels in the dorsal striatum of hemi-parkinsonian rat (50). The authors showed an 359 
upregulation of both the production and function of striatal GLT-1 after unilateral 6-OHDA lesioning. 360 
They hypothesized that an interplay between several glial and vesicular Glu transporter families might 361 
underlie abnormal glutamatergic neurotransmission in PD. There are several possible reasons for the 362 
increase in glial activity in the dopamine-depleted dorsal striatum. Firstly, the DA denervation may 363 
directly induce an increase in GS activity and, thus, glial hyperactivity. Secondly, the increase in Gln 364 
levels in the neuronal and/or the glial in the striatum of MPTP-intoxicated mice may be related to an 365 
increase in the Glu/Gln cycling and, by inference, synaptic glutamatergic transmission. Glu released 366 
by glutamatergic neurons has been shown to be taken up from the synapses rapidly by glia, through 367 
high-affinity Glu transporters, and converted into Gln by GS (51) Gln is subsequently released by 368 
astrocytes and taken up by neuronal terminals, in which it is converted enzymatically (glutaminase) 369 
back into Glu, thereby replenishing the neurotransmitter pool of Glu. This Glu/Gln cycle between 370 
neurons and astrocytes predominantly reflects the rates of Glu release and reuptake, thus providing an 371 
indication of synaptic glutamatergic activity (52-55).  372 
The present investigation did not show changes in other amino acids absolute levels after MPTP 373 
intoxication in the dorsal striatum and the NAc. Our results could be consistent with the absence of 374 
neuronal death in the striatum of PD. Furthermore, abundant NAA levels in unaffected GABAergic 375 
cells within the striatum may be masking its depletion, as dopaminergic nerve terminals affected by 376 
MPTP represent only 9% of all synapses in the striatum (56). 377 
A single challenge dose of levodopa (200 mg.kg-1) normalizes Glu, Gln and GABA levels in 378 
the dorsal striatum of MPTP-intoxicated mice, and also in the NAc for mice which had high GABA, 379 
Glu and Gln levels following severe dopaminergic denervation in VTA. This high dose of levodopa 380 
induced a decrease in the motor performance of controls probably related to the sedative effect of 381 
levodopa (57), but we nonetheless chose to use this dose, which is known to induce behavioral 382 
changes (58) and changes in levels of striatal metabolites (59) in MPTP-intoxicated mice. This high 383 
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dose of levodopa may attenuate hyperactivity of the glutamatergic cortico-striatal pathway, thereby 384 
decreasing the levels of Glu and, subsequently, Gln and GABA. Changes in Glu, Gln and GABA 385 
levels were not associated with changes in the intensity of immunolabelings performed 60 minutes 386 
after acute levodopa administration. Carta et al. (60) showed that, three days after priming, a single 387 
administration of levodopa yielded changes in GAD67 mRNA levels in all striatal neurons not 388 
observed in drug-naïve 6-OHDA-lesioned rats. We suggest that the short time interval between 389 
levodopa administration and immunolabelings (60 minutes) might account for the lack of change in 390 
the staining observed.  391 
In this study, we chose to use the rotarod and pole tests to assess the motor behavior of mice. 392 
The rotarod test is widely used in the evaluation of MPTP models (61). We observed significant 393 
differences in performance between MPTP-intoxicated mice and controls. In general, the results 394 
obtained depended strongly on the dose of the toxin administered.  Low and moderate MPTP doses 395 
produced no measurable impairment, whereas higher doses, such as that used here, have been shown 396 
to trigger performance deficiencies in the rotarod test (62). The pole test was used to assess the agility 397 
of the animals (27,61,62). This task involved skilled grasping by the forelimbs and maneuvering 398 
requiring the basal ganglia to be intact. The decrease in pole test performance described here was 399 
consistent with that reported in previous studies (26) and reflected a nigrostriatal dysfunction. 400 
Levodopa administration improved the rotarod performance and also the results to the pole test of 401 
MPTP-intoxicated mice. Taken together, these behavior results reflect a dysfunction of the basal 402 
ganglia that was improved by levodopa administration and thus confirms a striatal dopaminergic 403 
deficit following the dopaminergic lesion induced by MPTP in the SNc and the VTA. 404 
In conclusion, localized 1H NMR spectroscopy assessed the metabolic profile longitudinally in 405 
vivo according to the animal model and the therapeutic strategy in the dorsal striatum and NAc of the 406 
mice. A sufficient DA denervation in the VTA and the SNc induced increased levels of Glu, Gln and 407 
GABA in the NAc and the dorsal striatal nerve cell terminals.  408 
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Figure 1 –  
Chassain et al. - MRS in NAc of MPTP-intoxicated mice 
FIGURE 1. Experimental design.  
All behavior tests were performed between 8.00 am and 1.00 pm, for both groups of animals (n=10 
controls and n=10 MPTP-intoxicated mice). The first rotarod and pole tests were carried out the 
morning before the first saline or MPTP injection (d-5) and further tests were performed three days 
(d3) and ten days (d10) after the last injection. Animals were tested 60 minutes after the intraperitoneal 
administration of saline (0.2 ml) on d10 and 60 minutes after the administration of levodopa (200 
mg.kg-1 in 0.2 ml saline) on d11.  
NMR acquisitions were performed for both other groups of animals (n=10 controls and n=10 MPTP-
intoxicated mice) and begun ten days following the last MPTP injection, on d10. Spectra were 
acquired after the i.p. administration of saline (d10). One week later (d17), each animal was assessed 
again after the i.p. administration of levodopa. Animals were killed humanely once all the NMR 
acquisitions had been acquired (d24), 60 minutes after the i.p. administration of saline (n=5 controls 
and n=5 MPTP-intoxicated mice) and 60 minutes after the i.p. administration of levodopa (200 mg.kg-
1 in 0.2 ml saline; n=5 controls and n=5 MPTP-intoxicated mice). 
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FIGURE 2. Effect of MPTP treatment on TH-immunoreactivity in SNc and VTA coronal 
sections. 
A. Photomicrographs of representative posterior SNc and VTA sections stained with an antibody against 
TH. The tissues were collected 10 days after the last MPTP injection. The MPTP-intoxicated mice (5 
× 25 mg.kg-1, once daily for 5 days, i.p.) have fewer TH-positive neurons than the controls.  
Scale bar, 1 mm 
B. MPTP administration led to a significant decrease (85%) in the mean number of TH-immunoreactive 
neurons in the SNc, as shown by comparison with control values. A decrease of 44% was observed in 
the VTA. Means ± SD of five mice per group are presented, ***p < 0.001 and *p < 0.05 versus 
controls, in a two-way ANOVA followed by a Dunnett post-hoc test. 
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FIGURE 3. Time (s) spent on the rotarod for control mice (n=10) and MPTP-intoxicated mice 
(n=10). 
Saline or MPTP was injected once daily for 5 days. Animals were tested on the rotarod before saline 
or MPTP injection (d-5), and 3 days (d3) and 10 days (d10) after the last saline or MPTP injection. On 
d11, they were also assessed after levodopa (200 mg.kg-1; i.p.) administration. In the testing session, 
animals underwent four successive trials and the data presented are the means for these four trials. 
Results are presented as means ± SD (for 10 animals in each group). Within each group (controls or 
MPTP-intoxicated mice), asterisks (**) indicate a significant difference (p<0.01) with respect to the 
values obtained for the other trial sessions. #p<0.05 versus the corresponding control mean in repeated 
measures ANOVA followed by a Newman-Keuls post-hoc test. 
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FIGURE 4. Effect of MPTP on the pole test performances. 
Saline or MPTP was injected into the mice once daily for 5 days. The pole test was performed before 
saline or MPTP injection (d-5), 3 days (d3) and 10 days (d10) after the last saline or MPTP injection. 
On d11, the test was performed after levodopa (200 mg.kg-1; i.p.) administration. A mouse was placed 
head upwards close to the top of a rough-surfaced pole. The times required for the animal to turn 
completely (Tturn) and to reach the floor (TLA) were measured and are shown in A and in B, 
respectively. In the testing session, animals underwent three successive trials and the data presented 
are those obtained in the third trial. Results are presented as means ± SD (for 10 animals in each 
group). 
A. Tturn. In the control group, the mean obtained after levodopa administration on d11 was significantly 
higher than the other values (*p<0.05). In the MPTP-treated group, there was a significant difference 
between d10 on the one hand and d-5 and d3 on the other (**p<0.01). ##p<0.01 versus the 
corresponding control mean in a repeated measures ANOVA followed by a Newman-Keuls post-hoc 
test. 
B. TLA. Within the MPTP-treated group, there was a significant difference between the results obtained 
on d10 and those obtained on d-5 and d3 (**p<0.01). There was also a significant difference between 
the results obtained on d10 and d11 (+Ldopa) (*p<0.05). ##p<0.01 versus the corresponding control 
mean in a repeated measures ANOVA followed by a Newman-Keuls post-hoc test. 
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 FIGURE 5. Coronal MR images of the mouse brain with the volumes of interest (VOIs) 
centered on the dorsal striatum (A) and NAc (B) and NMR spectra for the corresponding brain 
regions in a control and an MPTP-intoxicated mouse, after the administration of saline and 
levodopa. 
The NMR images were acquired with a T2-weighted sequence, RARE (in-plane resolution 100 × 100 
µm/pixel, slice thickness 1 mm, TE = 36 ms, TR = 4.5 s).  
The NMR spectra were acquired with PRESS localization, with TE = 8.8ms, TR = 4000 ms, NS = 512 
for acquisition in the dorsal striatum and NS = 1024 for acquisition in the NAc; acquisition times were 
34 min and 68 min respectively. Spectra were line-broadened (5 Hz), and resonances were assigned as 
N-acetyl aspartate (NAA) at 2.008 ppm; γ-aminobutyric acid (GABA) at 2.27 ppm, glutamate (Glu) at 
2.34 ppm, glutamine (Gln) at 2.42 ppm; total creatine (tCr) at 3.022 ppm and 3.98 ppm, total choline 
(tCho) at 3.22 ppm; taurine (Tau) at 3.24-3.42 ppm; myoinositol (Myo-Ins) at 3.48-3.52 ppm; Glu + 
Gln complex (Glx) at 3.75 ppm. 
A. Spectra acquired for a VOI (2.0 × 2.0 × 2.0 mm) located on the dorsal part of the striatum, for a 
control mouse and an MPTP-intoxicated mouse, after the administration of saline and levodopa (200 
mg.kg-1) injection. 
B. Spectra acquired in a VOI (1.16 × 1.16 × 1.16 mm) located in the NAc, for a control mouse and an 
MPTP-intoxicated mouse, after the administration of saline and levodopa (200 mg.kg-1) injection. 
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 FIGURE 6. Absolute metabolite concentrations (mM) quantified in the dorsal striatum (A) and 
NAc (B) of controls and MPTP-intoxicated mice,  determinated by in vivo 
1
H NMR after saline 
and levodopa administration (200 mg.kg
-1
). 
Data are the means ± SD for 10 animals in the two controls groups and 10 animals in the two MPTP-
intoxicated mouse groups. Statistically significant differences are indicated for comparisons between 
the metabolite concentrations of controls and MPTP-intoxicated mice after the administration of saline 
and levodopa (200 mg.kg-1), for repeated measures analysis of variance followed by a Dunnett post-
hoc test. Significant differences were observed only in the dorsal part of the striatum and are indicated 
as: *p < 0.05; ***p < 0.001 controls + saline vs. MPTP-intoxicated mice + saline and #p < 0.05; ###p < 
0.001 MPTP-intoxicated mice + saline vs. MPTP-intoxicated mice + levodopa. 
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FIGURE 7. Individual data measured in the dorsal striatum and the NAc in relation to DA 
denervation of the SNc (A) and the VTA (B), respectively. 
Plotted are the GABA, Glu and Gln concentrations assessed by NMR spectroscopy in the dorsal 
striatum (A) and the NAc (B). Individual data points represent individual measures for the MPTP-
intoxicated mice, which have been sacrified for TH immunohistochemical staining, after saline and 
levodopa administration (n=5). The percentages of DA denervation in the SNc and the VTA are 
indicated on the right.  
Horizontal bars are the mean value for each group of subjects. 
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FIGURE 8. Effect of MPTP intoxication on GAD67, Glu and GS labeling in the dorsal striatum 
and NAc. 
 
A. Visualization of GAD67, Glu and GS immunolabeling in coronal slices of the dorsal part of the dorsal 
striatum and the NAc. The lines delimit the dorsal striatum and the area of the NAc in which 
immunoreactive cells were counted.  Typical labeling for GAD67, Glu and GS is shown (arrows) in 
the insets (×20).  
Scale bar, 1 mm. 
B. Quantitative analysis of the effect of DA denervation and DA replacement on the same markers in the 
dorsal striatum and the NAc (n=5 animals from each of the 4 experimental groups). Data are expressed 
as the mean number of immunoreactive cells ± SD. Statistical comparisons were performed by two-
way ANOVA, followed by Dunnett’s test. **p < 0.01 and ***p < 0.001 versus the control group. 
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FIGURE 9. Individual data measured in the dorsal striatum and the NAc in relation to DA 
denervation of the SNc (A) and the VTA (B), respectively. 
Plotted are the immunoreactive cells counted in the dorsal striatum and the NAc. Individual data 
points represent individual measures for the MPTP-intoxicated mice, which have been sacrified for 
TH immunohistochemical staining, after saline and levodopa administration (n=5). The percentages of 
DA denervation in the SNc and the VTA are indicated on the right. 
Horizontal bars are the mean value for each group of subjects. 
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